Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey, Marco Donia et al.|Aging|2011Cited by 707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey, Linda S. Steelman et al.|Oncotarget|2011Cited by 579
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathwaysJames A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Journal of Cellular Physiology|2011Cited by 171
Anticancer properties of the novel nitric oxide-donating compound (<i>S,R</i>)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide <i>in vitro</i> and <i>in vivo</i>Danijela Maksimović‐Ivanić, Stanislava Stošić‐Grujičić, Sanja Mijatović et al.|Molecular Cancer Therapeutics|2008Cited by 74
Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid–nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cellsSanja Mijatović, Ferdinando Nicoletti, Danijela Maksimović‐Ivanić et al.|Nitric Oxide|2008Cited by 26